ProPhase Labs to effect 1-for-10 reverse stock split to maintain Nasdaq listing

ProPhase Labs, Inc.

Stockholders approved reverse stock split on Nov 24, 2025; board approved Nov 30, 2025.
Certificate of Amendment filed Dec 2, 2025; split effective Dec 22, 2025 at 8:00 AM ET.
After split, approximately 5,768,951 shares of common stock will be outstanding.
No fractional shares; any fractional shares rounded up to whole share.
Reverse split intended to increase per-share price to meet Nasdaq continued listing requirements.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ProPhase Labs, Inc.: Amended Certificate of Incorporation to effect a 1-for-10 reverse stock split of common stock (effective 2025-12-02).

Change: charter amendment
Effective: 2025-12-02

Exact text from the filing

On December 2, 2025, ProPhase Labs, Inc., a Delaware corporation (the “Company”), filed a Certificate of Amendment (the “Certificate of Amendment”) to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0005 per share (the “Common Stock”) (the “Reverse Stock Split”). The Certificate of Amendment became effective on December 2, 2025.

View on SEC.gov

Browse all governance changes →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-027399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.